Lupin, a global pharmaceutical leader, has been recognized for its exceptional sustainability efforts, receiving the highest “A” leadership rating from the Climate Disclosure Project (CDP) for both Climate Change and Water Security. This prestigious recognition solidifies Lupin’s position among the world’s most sustainable and transparent companies. The double “A” rating reflects Lupin’s significant progress in mitigating climate risks, reducing carbon emissions, and ensuring responsible water management across its operations.<\/p>\n
Compared to its previous ratings, Lupin has made substantial improvements, upgrading from “A-” in 2024 and “B” and “C” in 2023 for climate and water, respectively. This remarkable achievement demonstrates Lupin’s commitment to sustainability and its proactive initiatives to minimize its environmental impact. Ramesh Swaminathan, Executive Director and Global CFO, expressed pride in earning the double “A” rating, attributing it to the company’s innovative approaches, collaborative efforts, and transparent practices.<\/p>\n
Lupin’s sustainability endeavors have also been recognized by S&P Global, which awarded the company an ESG score of 91 in 2025. This achievement places Lupin among an elite group of companies worldwide that have surpassed the 90-point threshold, demonstrating its best-in-class sustainability performance. The CDP’s strict framework has played a significant role in shaping and accelerating Lupin’s climate initiatives, driving ongoing progress and commitment to establishing new sustainability standards.<\/p>\n
The recognition from CDP and S&P Global underscores Lupin’s dedication to generating lasting value for its communities and the planet. As a global pharma leader, Lupin is committed to reducing its environmental impact through innovation, collaboration, and transparency, setting a high standard for sustainability in the industry. With its exceptional achievements, Lupin continues to demonstrate its position as a responsible and sustainable business leader, driving positive change and promoting a more environmentally conscious future.<\/p>\n","protected":false},"excerpt":{"rendered":"
Lupin, a global pharmaceutical leader, has been recognized for its exceptional sustainability efforts, receiving the highest “A” leadership rating from the Climate Disclosure Project (CDP) for both Climate Change and Water Security. This prestigious recognition solidifies Lupin’s position among the world’s most sustainable and transparent companies. The double “A” rating reflects Lupin’s significant progress in […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","fifu_image_url":"","fifu_image_alt":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[20,2],"tags":[],"class_list":["post-89870","post","type-post","status-publish","format-standard","hentry","category-lupin","category-pharma"],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":89848,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/24\/lupin-earns-top-cdp-a-rating-for-efforts-in-combating-climate-change-and-conserving-water\/","url_meta":{"origin":89870,"position":0},"title":"Lupin Earns Top CDP A Rating for Efforts in Combating Climate Change and Conserving Water","author":"Team Small News","date":"January 24, 2026","format":false,"excerpt":"Lupin Limited, a global pharmaceutical major, has achieved a significant milestone in its sustainability efforts by receiving the highest 'A' leadership rating from the Climate Disclosure Project (CDP) for its exceptional performance in Climate Change and Water Security. This recognition is a testament to Lupin's commitment to sustainability and transparency,\u2026","rel":"","context":"In "Lupin"","block_context":{"text":"Lupin","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/lupin\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89855,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/25\/lupin-achieves-prestigious-cdp-double-a-rating-for-excellence-in-climate-change-mitigation-and-water-stewardship\/","url_meta":{"origin":89870,"position":1},"title":"Lupin Achieves Prestigious CDP Double ‘A’ Rating for Excellence in Climate Change Mitigation and Water Stewardship","author":"Team Small News","date":"January 25, 2026","format":false,"excerpt":"Lupin, a global pharmaceutical company, has achieved a significant milestone in its sustainability journey by earning a double 'A' rating from CDP (formerly known as the Carbon Disclosure Project) for its leadership in climate action and water security. This prestigious rating recognizes Lupin's efforts to reduce its environmental impact and\u2026","rel":"","context":"In "Lupin"","block_context":{"text":"Lupin","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/lupin\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89844,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/23\/lupin-achieves-top-esg-score-from-cdp-for-efforts-in-combating-climate-change-and-ensuring-water-security-reported-by-chennai-patrika\/","url_meta":{"origin":89870,"position":2},"title":"Lupin Achieves Top ESG Score from CDP for Efforts in Combating Climate Change and Ensuring Water Security – Reported by Chennai Patrika.","author":"Team Small News","date":"January 23, 2026","format":false,"excerpt":"Lupin Limited, a global pharmaceutical major, has achieved a significant milestone in its sustainability efforts by receiving the highest 'A' leadership rating from the Climate Disclosure Project (CDP) for its exceptional accomplishments in Climate Change and Water Security. This recognition solidifies Lupin's position as a global leader in championing sustainability\u2026","rel":"","context":"In "Lupin"","block_context":{"text":"Lupin","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/lupin\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89810,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/16\/will-indian-pharmaceuticals-domestic-offerings-provide-a-buffer-against-pricing-pressures-from-the-us-market-in-the-third-quarter\/","url_meta":{"origin":89870,"position":3},"title":"Will Indian pharmaceuticals’ domestic offerings provide a buffer against pricing pressures from the US market in the third quarter?","author":"Team Small News","date":"January 16, 2026","format":false,"excerpt":"The Indian pharmaceutical industry is expected to have a mixed third quarter, with domestic formulations and specialty launches driving growth despite US pricing pressure. Companies like Sun Pharmaceuticals and Lupin are likely to lead the way, driven by their specialty businesses. Sun Pharma's revenue is expected to grow in the\u2026","rel":"","context":"In "Divi's Laboratories"","block_context":{"text":"Divi's Laboratories","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/divis-laboratories\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/divis-lab-logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/divis-lab-logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/divis-lab-logo.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/divis-lab-logo.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":89806,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/15\/us-sales-of-revlimid-decline-offset-by-strong-domestic-market-growth\/","url_meta":{"origin":89870,"position":4},"title":"US Sales of Revlimid Decline, Offset by Strong Domestic Market Growth","author":"Team Small News","date":"January 15, 2026","format":false,"excerpt":"The Indian pharmaceutical industry is bracing for a challenging earnings season in Q3, with expectations of muted margins due to the loss of patent exclusivity for the blockbuster blood cancer drug Revlimid in the US. Revlimid, which has generated over $100 billion in global sales, has been a significant revenue\u2026","rel":"","context":"In "Cipla"","block_context":{"text":"Cipla","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/cipla\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":89809,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/16\/indian-pharma-q3-preview-strong-domestic-formulations-segment-to-offset-us-pricing-challenges-scanx-trade\/","url_meta":{"origin":89870,"position":5},"title":"Indian Pharma Q3 Preview: Strong Domestic Formulations Segment to Offset US Pricing Challenges – scanx.trade","author":"Team Small News","date":"January 16, 2026","format":false,"excerpt":"The Indian pharmaceutical industry is expected to experience a mixed bag in the third quarter of the year, with domestic formulations likely to counterbalance the pressure from pricing in the US market. The sector's growth is anticipated to be driven by a strong performance in the domestic market, which is\u2026","rel":"","context":"In "Dr Reddy's"","block_context":{"text":"Dr Reddy's","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/dr-reddys\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"_links":{"self":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89870","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/comments?post=89870"}],"version-history":[{"count":0,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89870\/revisions"}],"wp:attachment":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/media?parent=89870"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/categories?post=89870"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/tags?post=89870"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}